10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Latest (Page 6)
Immunotherapy Rechallenge Falls Short in Advanced Kidney Cancer Trial
Phase 3 trial shows no benefit of adding immune checkpoint inhibitor to targeted therapy in RCC patients
INSIGHT Trial: Tailoring GIST Treatment with Precision Medicine
New trial evaluates ripretinib vs sunitinib in advanced GIST patients with specific KIT mutations
Pembrolizumab Boosts Survival in Early-Stage Melanoma: KEYNOTE-716 Trial Results
Adjuvant pembrolizumab shows sustained benefits for stage IIB/IIC melanoma patients in phase III trial.
Warming Up to Scalp Cooling: Electric Hand Warmers Boost Comfort for Breast Cancer Patients
Study shows electric hand warmers improve comfort for breast cancer patients using scalp cooling during chemo
Triplet Chemotherapy Shows Promise in Advanced Gastric Cancer: MATCH Trial Results
DOS chemotherapy improves tumor response in locally advanced gastric cancer compared to SOX regimen
PARP Inhibitor Shows Promise in Delaying Prostate Cancer Progression
Study explores rucaparib as ADT-sparing option for nonmetastatic prostate cancer with DNA repair defects
Ramucirumab Shows Promise After Immunotherapy in Advanced Gastroesophageal Cancer
Study suggests ramucirumab may benefit certain patients with advanced gastroesophageal cancer after immunotherapy
Breakthrough Combo Therapy Revolutionizes Advanced Bladder Cancer Treatment
New drug combination shows superior survival benefit for advanced bladder cancer in global trial.
Prostate Cancer Immunotherapy Combo Falls Short in Phase 2 Trial
AZD4635 with durvalumab or oleclumab shows limited efficacy in metastatic castration-resistant prostate cancer
Doxorubicin Addition to Sorafenib Fails to Improve Survival in Advanced Liver Cancer
Phase III trial shows doxorubicin plus sorafenib no better than sorafenib alone for advanced HCC.
Lower Dose Olanzapine: A Game-Changer for Chemo Nausea Prevention
Study finds lower olanzapine dose equally effective for chemo-induced nausea with less drowsiness.
Long-Term Study Challenges Rituximab Maintenance in Low-Burden Follicular Lymphoma
Extended follow-up of RESORT trial shows rituximab retreatment may be preferable to maintenance therapy.